IGXT - A Beautiful Spider Web of Large Company $$ and Potential Partnerships
My brother and I did an extensive research study of IGXT today. Did you know the following? -IGXT has a 3 year patent on Versafilm medicated film strips, for migraine and erectile dysfunction (ED) drug delivery -ED market is $2 billion plus, and patents have expired for Pfizer's Viagra -Migraine market is $670 million, and patents have expired for Merck -IGXT has a drug film production agreement with German company LTS, for Versafilm high volume production of the migraine drug, and ED drug -IGXT has a licensing arrangement partnership with private company Par Pharmeutical. Financial details of this agreement are not disclosed at this time, but will be invoked upon FDA approval for the migraine drug. - Par Pharma is #5 in size for generic drug sales and will take the lead on the migraine film and ED film distribution. -Par Pharmeutical has a proprietary division called Strativa Pharma. Strativa is already involved in film drug delivery products. -Par and Strativa Pharmaceutical are private and owned by TPG Capital. a $55.7 Billion Capital investment fund with deep pockets! -Par Pharma, on 1/21/14, just acquired JHP Pharmaceutical, a 450 employee pharma company that delivers 3 billion PILLS a year to customers. -Upon an FDA approval for migraine medication, could it be that Par Pharma is making a big time launch into medicated film production and leverage the customer relationships and sales for additional drugs that the JHP Pharmaceutical brings to the table in the area of PILL sales? - There are (at least) 10 FDA approved drugs/products already on the market for the film delivery drug method of consumption. Therefore, the likelihood of FDA appvoval is very strong on February 3! (This is not a new technology, only a new drug (migraine)). Summary: we are holding our stock through FDA approval on February 3. Additionally, we expect a buyout or significant market cap increase to $250 million + ($5 stock) upon FDA approval and subsequent stock buy ratings!
|